ClinicalTrials.gg
RecruitingNCT05377996Updated Jun 29, 2026

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

A Phase 1/2 interventional study of Emi-Le in Triple Negative Breast Cancer, Breast Cancer and Endometrial Cancer, sponsored by Day One Biopharmaceuticals, Inc.. Recruiting at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Day One Biopharmaceuticals, Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
360
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Triple Negative Breast Neoplasms with a site in United States — 159 open to participants now, 263 under way, 16 of them phase 3. Triple Negative Breast Neoplasms · United States.

Planned enrollment
53rd of 605
360 · median 52
Started
2022
with 44 others
Phase 1/2
107 of 645
30 open now
Primary completion
2027-02
later than 99 of 262 live
Registered
462nd of 645
by date

Among the 645 studies in Triple Negative Breast Neoplasms with a site in United States, this one is the 53rd largest by planned enrollment of the 605 interventional ones that give a count, is one of 45 that started in 2022, is one of 107 in phase 1/2, reaches primary completion later than 99 of the 262 other live ones, and was the 462nd registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

159 of the 645 studies in Triple Negative Breast Neoplasms with a site in United States are open now. Recruiting first, the newest first:

154 more — sign in →

All 159 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Triple Negative Breast Neoplasms with a site in United States, or all of them as a file.
02

Study summary

A Study of Emi-Le in Participants with Solid Tumors

Read the detailed description

This first-in-human (FIH) study will test the safety, side effects, and antitumor activity of a drug called Emi-Le ((Emiltatug Ledadotin, formerly XMT-1660). A side effect is anything a drug does to the body besides treating the disease.

Participants in the study will have cancer that has come back after a period of time during which the cancer could not be detected (recurrent), spread in the body near where it started (advanced) or spread through the body (metastatic).

The study will have three parts. The first part called Dose Escalation, will find out how much Emi-Le should be given to participants. The second part called Dose Expansion, will use the dose found in the first part to find out how safe Emi-Le is and if it works to treat solid tumors. The third part, the Phase 2 part of the trial, called EMBLEM-1, will find out if Emi-Le works to treat aggressive Adenoid Cystic Carcinoma and continue to check how safe Emi-Le is.

03

Conditions studied

  • Triple Negative Breast Cancer
  • Breast Cancer
  • Endometrial Cancer
  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cavity Cancer
  • Adenoid Cystic Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recurrent or advanced solid tumor and has disease
  • (ECOG) performance status 0 or 1
  • Participants in DES must have at least one (target) lesion as defined by version 1.1.
  • Tumor tissue, either archival or from a fresh tumor , available for testing or be willing to undergo a minimally invasive tumor biopsy to obtain tumor tissue for local testing, if not medically , prior to Cycle 1 Day 1
  • Brain magnetic resonance imaging (MRI) during the Screening period unless obtained within 30 days prior to Screening (based on standard clinical care), if they meet either of the following criteria:

    1. All participants with TNBC
    2. Participants with a history of or with neurologic symptoms or signs suspicious for brain metastases.

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with an Antibody Drug Conjugate (ADC) containing an auristatin payload. Prior treatment with another ADC containing other payloads is allowed.
  • Major surgery within 28 days of starting study treatment, systemic anticancer therapy within the time period of 28 days or 5 half-lives of the prior therapy before starting study treatment (14 days or 5 half-lives for small molecule targeted therapy), whichever is less, or palliative radiation therapy to the chest within 3 months of starting study treatment or to other anatomic sites within 14 days of starting study treatment.
  • Diagnosis of additional that required active treatment (including surgery, systemic therapy, and radiation) within 2 years prior to screening, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the breast or of the cervix.
  • Untreated (including new and progressive brain metastases), history of or carcinomatous meningitis.
  • Prior B7-H4 targeted treatment.
  • History of cirrhosis, hepatic fibrosis, esophageal or gastric varices, or other liver diseases.
  • Current severe, uncontrolled systemic disease (e.g. clinically significant cardiovascular, pulmonary, or metabolic disease) or intercurrent illness that could increase the risk of serious adverse events (SAEs) or interfere with per-protocol evaluations, in the judgment of either the Sponsor or the Investigator.
  • Clinically significant cardiovascular disease
  • Active keratitis (inflammation of the cornea of the eye)
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
360 participants (estimated)

Study arms

  • Experimental
    Emi-Le

    Single arm Emi-Le alone (monotherapy)

    Drug: Emi-Le

Interventions

  • DrugEmi-Le

    Emi-Le will be administered through a vein in your arm or port catheter (intravenously)

06

What researchers measure

Primary outcomes

  1. Frequency of adverse events that are considered dose-limiting toxicities (DLTs) and associated with Emi-Le during the first cycle of treatment (Dose Escalation)

    Determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of Emi-Le

    Time frame: 17 months

  2. Incidence of adverse events (Dose Escalation and Dose Expansion)

    Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose

    Time frame: 3 years

  3. Objective Response Rate (ORR) (Dose Expansion and EMBLEM-1)

    The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: approximately 3 years

Secondary outcomes

  1. Objective Response Rate (ORR) (Dose Escalation)

    The percentage of patients with a best overall response of complete or partial response as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Up to approximately 3 years

  2. Duration of response (DOR) (Dose Escalation, Dose Expansion, and EMBLEM-1)

    The time from when response criteria are first met until disease progression or death in participants who achieve a complete or partial response

    Time frame: Up to approximately 3 years

  3. Maximum observed plasma concentration of Emi-Le and payload (Cmax) (Dose Escalation and Dose Expansion)

    Cmax is the maximum concentration determined from the measured concentrations in plasma

    Time frame: Up to approximately 3 years

  4. Area under the concentration-time curve of Emi-Le and payload (AUC) (Dose Escalation and Dose Expansion)

    Area under the concentration-time curve for the last measurable concentration (AUC0-last) will be assessed as data permit

    Time frame: Up to approximately 3 years

  5. Antidrug antibodies (ADAs) and neutralizing antibodies (NAbs) (Dose Escalation, Dose Expansion, and EMBLEM-1)

    Assess the development of ADAs and NAbs to Emi-Le

    Time frame: Up to approximately 3 years

  6. Assess the overall survival (OS) of patients treated with Emi-Le (Dose Escalation, Dose Expansion, and EMBLEM-1)

    The time from the date of first dose of study treatment to the date of death due to any cause

    Time frame: Up to approximately 3 years

  7. Incidence of adverse events (EMBLEM-1)

    Assess the safety and tolerability of Emi-Le by determining the number of patients with adverse events from date of first dose to 60 days post last dose

    Time frame: 3 years

  8. Progression-free survival (PFS) (EMBLEM-1)

    The time from the date of first dose of study treatment until the first date at which disease progression is objectively documented or date of death due to any cause, whichever occurs first

    Time frame: Up to approximately 3 years

07

Study locations

26 of 26 sites recruiting
  • Mayo Clinic Comprehensive Cancer Center
    Phoenix, Arizona 85054, United States
    Recruiting
    • Felipe Batalini, MD · Contact
    • Felipe Batalini, MD · Principal investigator
  • UC Irvine Health-Chao Family Comprehensive Cancer Center
    Orange, California 92868, United States
    Recruiting
    • Ritesh Parajuli · Contact
    • Ritesh Parajuli · Principal investigator
  • UCSF Helen Diller Family Comprehensive Cancer Center
    San Francisco, California 94158, United States
    Recruiting
    • Laura Huppert, MD · Contact
    • Laura Huppert, MD · Principal investigator
  • UCLA David Geffen School of Medicine, Division of Hematology/Oncology
    Santa Monica, California 90404, United States
    Recruiting
    • Nicholas McAndrew, MD · Contact
    • Nicholas McAndrew, MD · Principal investigator
  • Mayo Clinic - Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
    • Pooja Advani, MD · Contact
    • Pooja Advani, MD · Principal investigator
  • Florida Cancer Specialists
    Sarasota, Florida 34232, United States
    Recruiting
    • Judy Wang · Contact
    • Judy Wang · Principal investigator
  • Moffitt Cancer Center
    Tampa, Florida 33612, United States
    Recruiting
    • Hyo Han, MD · Contact
    • Hyo Han, MD · Principal investigator
  • Winship Cancer Institute, Emory University
    Atlanta, Georgia 30322, United States
    Recruiting
    • Kevin Kalinsky, MD · Contact
  • Northwestern University
    Chicago, Illinois 60611, United States
    Recruiting
    • Patricia Robinson, MD · Contact
    • Patricia Robinson, MD · Principal investigator
  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Gerburg Wulf, MD · Contact
    • Gerburg Wulf, MD · Principal investigator
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
    Recruiting
    • Antonio Giordano, MD, PhD · Contact
  • Henry Ford Health Hospital
    Detroit, Michigan 48202, United States
    Recruiting
    • Amy Weise, MD · Contact
  • Mayo Clinic - Rochester
    Rochester, Minnesota 55905, United States
    Recruiting
    • Roberto Leon-Ferre, MD · Contact
    • Roberto Leon-Ferre, MD · Principal investigator
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
    Recruiting
    • Liawaty Ho, MD · Contact
    • Liawaty Ho, MD · Principal investigator
  • New York University Langone Health
    New York, New York 10016, United States
    Recruiting
    • Nancy Chan, MD · Contact
  • ICHAN School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Amy Tiersten · Contact
    • Amy Tiersten · Principal investigator
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Nour Abuhadra, MD · Contact
  • Stephenson Cancer Center Oklahoma University Health
    Oklahoma City, Oklahoma 73104, United States
    Recruiting
    • Debra Richardson, MD · Contact
    • Debra Richardson, MD · Principal investigator
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57105, United States
    Recruiting
    • David C. Starks, MD · Contact
    • David C. Starks, MD · Principal investigator
  • Sarah Cannon Research Institute (SCRI)
    Nashville, Tennessee 37203, United States
    Recruiting
    • Erika P Hamilton, MD · Contact
  • Texas Oncology, P.A.
    Dallas, Texas 75251, United States
    Recruiting
    • Joyce O'Shaughnessy, MD · Principal investigator
  • MD Anderson
    Houston, Texas 77030, United States
    Recruiting
    • Funda Meric-Bernstam · Contact
    • Funda Meric-Bernstam · Principal investigator
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
    Recruiting
    • Kristen Kelley, MD · Contact
    • Kristen Kelley, MD · Principal investigator
  • NEXT Oncology Virginia
    Fairfax, Virginia 22031, United States
    Recruiting
    • Alex Spira, MD, PhD · Contact
  • Fred Hutchinson Cancer Center
    Seattle, Washington 09109, United States
    Recruiting
    • Jennifer Specht, MD · Contact
  • Summit Cancer Centers
    Spokane, Washington 99208, United States
    Recruiting
    • Arvind Chaudhry, MD, PhD · Contact
08

References and documents

Publications

  • Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, Chin CN, Dirksen A, Du B, Duvall JR, Higgins S, Kozytska MV, Bellovoda K, Faircloth C, Lee D, Li F, Qin L, Routhier C, Shaw P, Stevenson CA, Wang J, Wongthida P, Ter-Ovanesyan E, Ditty E, Bradley SP, Xu L, Yin M, Yurkovetskiy AV, Mosher R, Damelin M, Lowinger TB. Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer. Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786. PubMed 37294948 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Feb 2027, 54 months after the start.

Of 70 industry-sponsored phase 1/2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 77. This study's planned 54 months is close to that.

Counting every sponsor, half of 118 studies reached it within 56 months; a quarter within 43 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 17, 2022
StartActual
Aug 15, 2022
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2027
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05377996
Lead sponsor
Day One Biopharmaceuticals, Inc.
Responsible party
Sponsor
First posted
May 17, 2022
Start date
Aug 15, 2022
Primary completion
Feb 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jun 29, 2026

Study contacts

Day One Clinical Trials Information
Contact
clinicaltrials@dayonebio.com
1-650-484-0899
Robert Burger, MD
study director · Day One Biopharmaceuticals, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion